Paradoxical oncogenesis: are all BRAF inhibitors equal?
- PMID: 23795808
- DOI: 10.1111/pcmr.12132
Paradoxical oncogenesis: are all BRAF inhibitors equal?
Abstract
Cutaneous squamous cell carcinoma (cSCC) is a concerning toxicity with BRAF inhibitors in the treatment for melanoma. While the two drugs shown to improve survival, vemurafenib, and dabrafenib, have similar efficacy, the reported rates of cSCC are quite different. Drawing upon preclinical and clinical trial data, this article discusses the potential factors behind the different cSCC incidences reported with the two BRAF inhibitors and provides a strategic approach to understand this issue further.
Keywords: BRAF inhibitor; dabrafenib; melanoma; secondary malignancy; squamous cell carcinoma; vemurafenib.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials